Hennion & Walsh Asset Management Inc. Grows Stake in Grifols, S.A. (NASDAQ:GRFS)

Hennion & Walsh Asset Management Inc. raised its holdings in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 20.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 266,005 shares of the biotechnology company's stock after acquiring an additional 44,818 shares during the period. Hennion & Walsh Asset Management Inc.'s holdings in Grifols were worth $1,891,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GRFS. Charles Schwab Investment Management Inc. boosted its position in shares of Grifols by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock worth $247,000 after buying an additional 1,657 shares during the period. Versant Capital Management Inc acquired a new position in shares of Grifols during the first quarter worth about $28,000. HighTower Advisors LLC boosted its position in shares of Grifols by 28.3% during the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock worth $133,000 after buying an additional 3,936 shares during the period. Blue Trust Inc. boosted its position in shares of Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after buying an additional 4,970 shares during the period. Finally, Corient Private Wealth LLC boosted its position in shares of Grifols by 11.0% during the fourth quarter. Corient Private Wealth LLC now owns 50,883 shares of the biotechnology company's stock worth $379,000 after buying an additional 5,040 shares during the period.

Grifols Price Performance

NASDAQ:GRFS traded up $0.01 during trading hours on Monday, reaching $8.83. 350,555 shares of the company were exchanged, compared to its average volume of 1,162,295. The company has a market capitalization of $6.07 billion, a P/E ratio of 7.55 and a beta of 0.53. Grifols, S.A. has a 1-year low of $5.79 and a 1-year high of $9.96. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The business has a 50 day moving average of $7.48 and a 200 day moving average of $7.53.

Analyst Ratings Changes

Several research firms have recently weighed in on GRFS. Morgan Stanley began coverage on Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating for the company. Wall Street Zen raised Grifols from a "hold" rating to a "buy" rating in a research report on Friday, May 23rd.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.